Bicycle Therapeutics plc
BCYC
$4.72
$0.020.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,193.28% | 338.49% | -68.81% | -48.91% | -30.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,193.28% | 338.49% | -68.81% | -48.91% | -30.44% |
| Cost of Revenue | -4.28% | 24.02% | 77.31% | 73.83% | -6.24% |
| Gross Profit | 104.61% | -4.44% | -121.87% | -252.52% | 3.42% |
| SG&A Expenses | 1.09% | -0.96% | 15.95% | 25.19% | 165.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.57% | 16.18% | 59.84% | 56.46% | 17.97% |
| Operating Income | 69.19% | -2.67% | -85.65% | -121.35% | -22.73% |
| Income Before Tax | 64.32% | -8.56% | -99.47% | -129.78% | -8.52% |
| Income Tax Expenses | 216.91% | 105.95% | -300.87% | -210.57% | -438.13% |
| Earnings from Continuing Operations | 61.13% | -16.33% | -98.31% | -128.72% | -5.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.13% | -16.33% | -98.31% | -128.72% | -5.61% |
| EBIT | 69.19% | -2.67% | -85.65% | -121.35% | -22.73% |
| EBITDA | 70.44% | -3.44% | -88.65% | -128.13% | -23.35% |
| EPS Basic | 61.30% | -15.81% | -48.90% | -40.68% | 35.13% |
| Normalized Basic EPS | 74.02% | -10.00% | -49.75% | -41.35% | 29.08% |
| EPS Diluted | 61.30% | -15.81% | -48.90% | -40.68% | 35.13% |
| Normalized Diluted EPS | 74.02% | -10.00% | -49.75% | -41.35% | 29.08% |
| Average Basic Shares Outstanding | 0.45% | 0.46% | 33.20% | 62.59% | 62.78% |
| Average Diluted Shares Outstanding | 0.45% | 0.46% | 33.20% | 62.59% | 62.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |